. 2022 Jan 25;14(3):604. doi: 10.3390/cancers14030604

Table 1.

Densities of nucleated profiles of tumor infiltrating lymphocytes (Q_A) per individual ROI associated with time to recurrence and disease-free survival (univariable analysis).

	Q_A	TTR			DFS
	Q_A	HR	95% CI	p	HR	95% CI	p
Tumor Center
CD3,n = 67 p *= 0.030 , 0.014** ^†	int vs. low	0.61	0.26–1.40	0.243	0.62	0.31–1.23	0.170
CD3,n = 67 p *= 0.030 , 0.014** ^†	high vs. low	0.20	0.06–0.66	0.008	0.28	0.12–0.66	0.003
CD8,n = 67 p *= 0.010 , 0.004** ^†	int vs. low	0.34	0.14–0.81	0.014	0.53	0.27–1.07	0.075
CD8,n = 67 p *= 0.010 , 0.004** ^†	high vs. low	0.25	0.09–0.70	0.008	0.23	0.09–0.55	0.001
CD20,n = 67 p *= 0.031 , 0.020** ^†	int vs. low	0.63	0.27–1.48	0.289	0.67	0.32–1.37	0.270
CD20,n = 67 p *= 0.031 , 0.020** ^†	high vs. low	0.18	0.05–0.65	0.009	0.27	0.11–0.69	0.006
Inner invasive margin
CD3,n = 65 p *= 0.014 , 0.005** ^†	int vs. low	0.77	0.33–1.79	0.545	0.77	0.39–1.55	0.472
CD3,n = 65 p *= 0.014 , 0.005** ^†	high vs. low	0.14	0.04–0.54	0.004	0.24	0.09–0.59	0.002
CD8,n = 66 p *= 0.029 , 0.006** ^†	int vs. low	0.52	0.23–1.19	0.120	0.77	0.40–1.51	0.455
CD8,n = 66 p *= 0.029 , 0.006** ^†	high vs. low	0.23	0.08–0.69	0.009	0.22	0.09–0.57	0.002
CD20,n = 66 p *= 0.002 , <0.001** ^†	int vs. low	0.38	0.16–0.90	0.026	0.36	0.18–0.74	0.005
CD20,n = 66 p *= 0.002 , <0.001** ^†	high vs. low	0.09	0.02–0.36	0.001	0.13	0.05–0.35	<0.001
Outer invasive margin
CD3,n = 65 p = 0.354 *, 0.280 ^†	int vs. low	0.66	0.26–1.65	0.371	0.58	0.27–1.23	0.153
CD3,n = 65 p = 0.354 *, 0.280 ^†	high vs. low	0.47	0.17–1.32	0.151	0.56	0.26–1.24	0.153
CD8,n = 66 p = 0.325 *, 0.061 ^†	int vs. low	0.55	0.22–1.37	0.197	0.48	0.23–0.98	0.044
CD8,n = 66 p = 0.325 *, 0.061 ^†	high vs. low	0.50	0.18–1.36	0.174	0.41	0.18–0.92	0.030
CD20,n = 66 p = 0.680 *, 0.475 ^†	int vs. low	0.99	0.40–2.44	0.986	0.99	0.49–2.00	0.974
CD20,n = 66 p = 0.680 *, 0.475 ^†	high vs. low	0.68	0.25–1.87	0.452	0.65	0.29–1.45	0.290
Peritumor liver
CD3, n = 64	int vs. low	0.53	0.20–1.38	0.193	0.74	0.34–1.63	0.452
p = 0.418 *, 0.676 ^†	high vs. low	0.78	0.30–2.04	0.608	0.95	0.42–2.14	0.902
CD8, n = 65	int vs. low	0.82	0.33–2.04	0.663	1.09	0.52–2.26	0.828
p = 0.753 *, 0.952 ^†	high vs. low	1.15	0.43–3.04	0.780	1.14	0.50–2.62	0.757
CD20, n = 65	int vs. low	0.24	0.09–0.64	0.004	0.43	0.20–0.92	0.030
p= 0.014 *, 0.053 ^†	high vs. low	0.72	0.30–1.71	0.452	0.86	0.40–1.84	0.699

For all cells and regions of interest, the raw densities of nucleated profiles of CD3+, CD8+ and CD20+ tumor infiltrating lymphocytes per area section (mm²) were converted into percentiles and then categorized into low (0–25 percentile), intermediate (25–70 percentile) or high (70–100 percentile). Hazard ratios shows the relative risk compared with 1 for the low density. Bold values indicate statistical significance at the p < 0.05 level. * Type 3 Wald test p value for all 3 levels of cell densities for TTR. ^† Type 3 Wald test p value for all 3 levels of cell densities for DFS. Abbreviations: HR: hazard ratio; CI: confidence interval; TTR: time to recurrence; DFS: disease-free survival; int: intermediate.